ATXIAVENUE THERAPEUTICS, INC.

Nasdaq avenuetx.com


$ 2.42 $ 0.14 (5.77 %)    

Wednesday, 07-Aug-2024 15:06:47 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 2.475
$ 2.34 x 250
-- x --
-- - --
$ 2.25 - $ 82.50
9,891
na
3.54M
$ 0.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-25-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-30-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-13-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 03-01-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-11-2017 06-30-2017 10-Q
30 05-12-2017 03-31-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 avenue-therapeutics-q2-eps-643-misses-105-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(6.43) per share which missed the analyst consensus estimate of...

 avenue-therapeutics-q1-eps-1540-misses-900-estimate

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(15.40) per share which missed the analyst consensus estimate o...

 avenue-therapeutics-may-offer-shares-of-common-stock-having-offering-price-of-up-to-39m-from-time-to-time-through-agent

- SEC Filing

 why-avenue-therapeutics-atxi-stock-is-falling-sharply

Avenue Therapeutics shares are trading lower by 20.7% during Monday's session. The company announced the exercise of warran...

 why-avenue-therapeutics-atxi-shares-are-getting-hammered

Avenue Therapeutics shares are trading lower by 28.5% during Wednesday's session. The company is implementing a 1-for-75 re...

 avenue-therapeutics-plans-to-effect-1-for-75-reverse-split-of-its-issued-and-outstanding-common-stock

Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION